Cover Image

Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients failing or intolerant to first-line second-generation tyrosine kinase inhibitor treatment: results of the prospective PONS trial

Introduction: In chronic myeloid leukemia patients, second-line treatment requires careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowered dose should be evaluated in this setting. Methods: We studied a lowered dose...

Full description

Saved in:
Bibliographic Details
Main Authors: Le Coutre, Philipp (Author) , Burchert, Andreas (Author) , Saußele, Susanne (Author) , Schwarzer, Thekla (Author) , Stintzing, Sebastian (Author) , Pelzer, Uwe (Author) , Bullinger, Lars (Author) , Elmaaḡaçlı, Ahmet Hayri (Author) , Jehn, Christian-Friedrich (Author) , Stegelmann, Frank (Author) , Hochhaus, Andreas (Author) , Ernst, Thomas (Author) , Göthert, Joachim Rudolf (Author)
Format: Article (Journal)
Language:English
Published: May 05 2025
In: Acta haematologica

ISSN:1421-9662
DOI:10.1159/000545826
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000545826
Verlag, lizenzpflichtig, Volltext: https://karger.com/aha/article-abstract/doi/10.1159/000545826/926666/Favorable-Rates-of-Cardiovascular-Events-with?redirectedFrom=fulltext
Get full text
Author Notes:Philipp le Coutre, Andreas Burchert, Susanne Saußele, Thekla Schwarzer, Sebastian Stintzing, Uwe Pelzer, Lars Bullinger, Ahmet Elmaagacli, Christian Jehn, Frank Stegelmann, Andreas Hochhaus, Thomas Ernst, Joachim R. Göthert
Description
Summary:Introduction: In chronic myeloid leukemia patients, second-line treatment requires careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowered dose should be evaluated in this setting. Methods: We studied a lowered dose of 30 mg ponatinib in second line in patients selected toward a low cardiovascular risk. In 22 screened patients, ponatinib was started in 18 patients previously treated with imatinib (n = 3), dasatinib (n = 9), or nilotinib (n = 6). Patients were frequently monitored for cardiovascular toxicities by testing of blood pressure, vital signs, ankle brachial index or duplex, oral glucose tolerance test, echocardiography, ECG, and fundoscopy. The study protocol allowed dose reductions in patients achieving MMR. Both previously resistant or intolerant patients were recruited. Results: No serious cardiovascular events were observed, and low-grade cardiovascular toxicity was negligible. By 12 months, 13 patients (92.9%) were in complete hematologic remission, 10 patients (55.6%) were in MMR, and 5 patients (27.8%) were in MR4. Most importantly, we demonstrated that thorough monitoring of cardiovascular risk is feasible. Conclusions: We demonstrated that a lowered dose of 30 mg ponatinib in selected patients can be maintained without serious cardiovascular complications, provided cardiovascular risk monitoring is performed. In our patient cohort, this approach resulted in favorable response rates.
Item Description:Gesehen am 20.10.2025
Physical Description:Online Resource
ISSN:1421-9662
DOI:10.1159/000545826

Similar Items